-transparent.png){kind=logo}
In 20 normal persons and in 57 patients with heart diseases with functional class I-IV (according to the classification of the New York Heart Association) the 24 hour urinary excretion of the catecholamines adrenaline, noradrenaline and dopamine and of the O2-methylated degradation products metanephrine and normetanephrine was determined. The 3 catecholamines and the 2 O-methylated derivatives were measured simultaneously using chromatographic extraction and purification (Bio-Rex 70) and selective flurometric determination. The following results could be obtained: 1. The urinary excretion of noradrenaline increased with increasing severity of the heart disease. 2. In patients with severe congestive heart failure (functional class IV) in addition the adrenaline excretion in addition the adrenaline excretion increased significantly. 3. There was no relationship between the urinary excretion of dopamine and the severity of the heart disease. 4. The ratio of noradrenaline excretion to dopamine excretion increased with increasing severity of the heart disease, indicating an increased activity of dopamine-mu-hydroxylation in patients with congestive heart failure. 5. The excretion of the O-methylated degradation products metanephrine and normetanephrine in normal persons and in patients with heart diseases paralleled the excretion of the corresponding catecholamines adrenaline and noradrenaline. This indicates, that increased excretion of noradrenaline and adrenaline (Class IV) in patients with heart failure was not due to impaired catecholamine-degradation but indead to increased catecholamine-release indicating increased sympatho-adrenergic activity. These results show in addition that also in patients with heart failure O-methylation represents still the main degradation step for the inactivation of the circulating catecholamines. 6. The relationship of toal excretion of 0-methylated derivates to total excretion of adrenaline and noradrenaline, however, decreased with increasing severity of heart disease, indicating a relative impairment of O-methylation under the condition of severe congestive heart failure.
W Mäurer, and
Y Yoshida, and
W Kübler
July 1966,
Clinica chimica acta; international journal of clinical chemistry,
W Mäurer, and
Y Yoshida, and
W Kübler
March 1970,
Revue europeenne d'etudes cliniques et biologiques. European journal of clinical and biological research,
W Mäurer, and
Y Yoshida, and
W Kübler
August 1968,
Schweizerische medizinische Wochenschrift,
W Mäurer, and
Y Yoshida, and
W Kübler
January 1973,
Sbornik lekarsky,
W Mäurer, and
Y Yoshida, and
W Kübler
January 1963,
Acta Universitatis Carolinae. Medica,
W Mäurer, and
Y Yoshida, and
W Kübler
April 1988,
Giornale di clinica medica,
W Mäurer, and
Y Yoshida, and
W Kübler
May 1959,
Clinica chimica acta; international journal of clinical chemistry,
W Mäurer, and
Y Yoshida, and
W Kübler
January 1978,
Verhandlungen der Deutschen Gesellschaft fur Innere Medizin,
W Mäurer, and
Y Yoshida, and
W Kübler
March 1979,
Canadian journal of physiology and pharmacology,
W Mäurer, and
Y Yoshida, and
W Kübler
June 1979,
Revista clinica espanola,
